and the training necessary to utilize novel manufacturing technologies.

Overall, the FDA Act will reauthorize four user fee programs created to expedite the review of critical medical products that people depend on to live healthier and longer lives.

In addition to delivering drugs and medical devices to people faster, the FDA Act includes policies to lower healthcare costs, spur more lifesaving innovation, secure our supply chains, and provide hope to patients in need of breakthrough drugs and therapies. Those treatments won't make it to patients if FDA doesn't have the right tools to keep up with science, such as accelerated approval pathway.

Chairman PALLONE and I initially had quite different versions for how the accelerated approval process should be updated, but we focused on where we could agree. We streamlined the process to remove drugs that no longer show effectiveness in post-market studies and made sure that real-world evidence can be used. We also made sure rare diseases aren't left out of accelerated approval because of a lack of knowledge and interest in developing the biomarkers necessary.

Lastly, not only is this legislation necessary to preserve patient access to new medical breakthroughs, it is fiscally responsible. It ensures FDA's timely review of medical products at a reduced cost to the taxpayer, and it reduces the deficit.

Many other members have priorities included in this legislation.

Mr. BUCHANAN has a bipartisan bill to make sure that we are moving away from preclinical testing on animal models where alternatives can work just as well.

Messrs. GRIFFITH, CARTER, and HUDSON all have legislation to hold FDA accountable regarding inspections of foreign manufacturing facilities and pilots for FDA to give companies with novel manufacturing technologies more certainty.

Mr. GUTHRIE has a solution included to help insurers plan for breakthrough future treatments. This will help patients avoid sticker shock and protect earlier access to those treatments.

These are just some of more than a dozen examples of member priorities in the FDA Act. I strongly urge support of this legislation, and I encourage all of my colleagues to vote ''yes.''

Mr. Speaker, this is for patients and families in every district and every corner of America who are relying on a generic drug, a medical device, like a pacemaker, or a novel cancer treatment. Those patients are relying on Congress to do its job so their drug approval isn't stalled.

I think about all the advocates, the hundreds of disease and rare disease groups who come to the people's House to share their stories with us. They have an extraordinary amount of hope in the promise of American innovation for new cures and access to treatments.

For them, I am supporting this legislation, and I am committed to work to get this signed into law on time.

Mr. PALLONE. Madam Speaker, I am prepared to close, and I reserve the balance of my time.

Mr. GUTHRIE. Madam Speaker, I yield myself such time as I may consume.

Madam Speaker, through the years, since this medical device fee has been put into place, has Congress taken action to make sure an agency is efficient; that it does its job to make sure that our drugs and medical devices have efficacy, but also are safe? So we make them more efficient and we have drug companies, device companies, other companies, generic companies, trying to get their devices or their pharmaceuticals approved so they can bring them on the marketplace that are safe and efficient. So this is really an example of Congress working together to move this process forward.

And the innovations that have come out in the last few years, if we look at what has gone on in the diabetes world with the artificial pancreas, all the pumps and insulin devices, to hepatitis C, pharmaceuticals and other ways, and just so much more, what is going to happen in the next 5 years as we continue to move this process forward?

We had a hearing in the Subcommittee on Health on ALS, and we had an ALS patient before us who just wants hope. So all of that is accounted for in this process.

We, as Members of Congress, we, as members of the Committee on Energy and Commerce have worked together to make the process streamlined, to make sure we have efficient, efficacy, and safe products. Our hope and our prayers from this is the science will come into place so those who testified before our committee with rare diseases will have the opportunity and hope to be healed.

I urge my colleagues to support this piece of legislation. A lot of hard work went into it. A lot of lives can be affected by it. I encourage everyone to vote for it.

Madam Speaker, I yield back the balance of my time.

Mr. PALLONE. Madam Speaker, I yield myself such time as I may consume.

Madam Speaker, I couldn't agree more with what Ranking Member GUTHRIE said, and also our full committee ranking member, Mrs. RODGERS. This is a product of a lot of hard work on behalf of members, as well as the staff that are here, and others. It is really great that we are able to do it in a timely fashion because we want the FDA to be able to operate, not to have to put out pink slips because the authorization expires in September.

This is really a reauthorization that does a lot more than just reauthorize the current programs. It really is going to make a difference in terms of our ability to innovate and also affect access to generic drugs.

Madam Speaker, I encourage all Members to support the bill. We are going to work hard to get this passed in the Senate in a timely fashion.

Madam Speaker, I yield back the balance of my time.

The SPEAKER pro tempore (Ms. PINGREE). The question is on the motion offered by the gentleman from New Jersey (Mr. PALLONE) that the House suspend the rules and pass the bill, H.R. 7667, as amended.

The question was taken.

The SPEAKER pro tempore. In the opinion of the Chair, two-thirds being in the affirmative, the ayes have it.

Mr. HARRIS. Madam Speaker, on that I demand the yeas and nays.

The SPEAKER pro tempore. Pursuant to section 3(s) of House Resolution 8, the yeas and nays are ordered.

Pursuant to clause 8 of rule XX, further proceedings on this motion are postponed.

ANNOUNCEMENT BY THE SPEAKER PRO TEMPORE

The SPEAKER pro tempore. Proceedings will resume on questions previously postponed.

Votes will be taken in the following order:

Motions to suspend the rules and pass:

H.R. 6087; and

S. 3823.

The first electronic vote will be conducted as a 15-minute vote. Pursuant to clause 9 of rule XX, remaining electronic votes will be conducted as 5-minute votes.

IMPROVING ACCESS TO WORKERS' COMPENSATION FOR INJURED FEDERAL WORKERS ACT OF 2022

The SPEAKER pro tempore. Pursuant to clause 8 of rule XX, the unfinished business is the vote on the motion to suspend the rules and pass the bill (H.R. 6087) to amend chapter 81 of title 5, United States Code, to cover, for purposes of workers' compensation under such chapter, services by physician assistants and nurse practitioners provided to injured Federal workers, and for other purposes, as amended, on which the yeas and nays were ordered.

The Clerk read the title of the bill.

The SPEAKER pro tempore. The question is on the motion offered by the gentleman from Connecticut (Mr. COURTNEY) that the House suspend the rules and pass the bill, as amended.

The vote was taken by electronic device, and there were—yeas 325, nays 83, not voting 19, as follows:

[Roll No. 233]

YEAS—325

Adams	Bass	Boyle, Brendan F.
Aderholt	Beatty	Brooks
Aguilar	Bera	Brown (MD)
Allen	Bergman	Brown (OH)
Allred	Beyer	Brownley
Amodei	Bilirakis	Budd
Armstrong	Bishop (GA)	Bush
Auchincloss	Blumenauer	Bustos
Axne	Blunt Rochester	Butterfield
Bacon	Bonamici	Calvert
Baird	Bost	Carbajal
Banks	Bourdeaux	Cárdenas
Barragán	Bowman	